Tabuk University Faculty of Applied Medical Sciences Department Of Medical Lab. Technology 3 rd Year – Level 5 – AY 1434-1435 1.

Slides:



Advertisements
Similar presentations
Basic coagulation techniques and Quality control issues
Advertisements

1 THROMBOPHILIA. 2 Thrombophilia is technical term for hypercoagulable state Thrombosis (arterial or venous) is produced by a shift in the balance between.
Thrombophilia. Now considered a multicausal disease, with an interplay of acquired and genetic thrombotic risk factors Approximately half of venous thromboembolic.
Hemostasis & Thrombosis: Platelet Disorders Beth A. Bouchard BIOC 212: Biochemistry of Human Disease Spring 2005.
Bachelor of Chinese Medicine, The University of Hong Kong Bleeding disorders Dr. Edmond S. K. Ma Division of Haematology Department of Pathology The University.
Haemostasis Tiffany Shaw MBChB II Haemostasis Pathway Injury Collagen exposure Tissue Factor Platelet adhesion Coagulation Cascade Release reaction.
HAEMATOLOGY MODULE: COAGULATION DISORDERS 1 Adult Medical-Surgical Nursing.
Vascular Pharmacology
Pathology of Coagulation I- Deficiency of Coagulation Factors II- II- HYPERCOAGULABLE STATES.
Thrombophilic states. Thrombophilic state is characterized by a shift in the coagulation balance in favour of hypercoagulability – i.e. easier and oftener.
MLAB Coagulation Keri Brophy-Martinez Thrombophilia.
Pathology 430/826 Thrombosis David Lillicrap. Cardiovascular Disease 30% of all deaths in Canada 54% ischemic heart disease 20% stroke 23% heart attack.
Clinical Genetics M. Kent Froberg, MD Purpose This lecture is designed to illustrate two examples of the use of molecular genetics in the clinical.
Dr msaiem Acquired Coagulation Disorders Dr Mohammed Saiem Al-dahr KAAU Faculty of Applied Medical Sciences.
Week 6: Secondary Hemostasis Plasmatic factors Plasmatic factors Intrinsic pathway Intrinsic pathway Extrinsic pathway Extrinsic pathway Specimen Specimen.
Week 7: Fibrinolysis and Thrombophilia Secondary fibrinolysis Secondary fibrinolysis Primary fibrinolysis Primary fibrinolysis Plasminogen Plasminogen.
Dr MOHAMMED H SAIEMALDAHR FACULTY of Applied Medical Sciences
Lecture NO- 12- Dr: Dalia Kamal Eldien.  Coagulation: Is the process by which blood changes from a liquid to a clot. Coagulation begins after an injury.
Thrombophilias Sharon Sams. Objectives Overview of etiology of hypercoagulability Available tests Clinical correlation or “What do I do with these results?”
PATHOPHYSIOLOGY OF THROMBOSIS “Virchow’s Triad” 1.Injury to blood vessels Trauma, atherosclerosis, surgery 2.Stasis of blood Immobility, venous incompetence,
Dr Nico Lategan MBChB, MMed (Haematology)
Tabuk University Faculty of Applied Medical Sciences Department Of Medical Lab. Technology 3 rd Year – Level 5 – AY
Hemostasis and Blood Coagulation
Anti-phospholipid syndrome Clinton Mitchell 5th year Haematology.
Thrombophilia— Hypercoagulable States Gabriel Shapiro, MD, FACP.
Dr Mahvash Khan MBBS, MPhil. ◦ Occurs inside the blood vessels, it is also called fibrinolysis ◦ Occurs due to a substance known as plasmin (fibrinolysin)
HEMOSTASIS/THROMBOSIS III Regulation of Coagulation/Disseminated Intravascular Coagulation.
Chapter 34 Vascular Thrombosis Due to Hypercoagulable States
Approach to Bleeding Disorders
1 HAEMOSTASIS. 2 Definition Haemostasis is a complex sequence of physical and biochemical changes induced by damage to tissues and blood vessels, which.
APPROACH TO BLEEDING DISORDERS. History of Bleeding Spontaneous vs. trauma/surgery-induced Ecchymoses without known trauma Medications or nutritional.
Coagulation Concepts A review of hemostasis Answers are in the notes pages.
Haemostasis Presented by Dr Azza Serry. Learning Objectives  Definition.  Clotting mechanism.  What keeps blood in fluid status  Control of blood.
Thrombophilia (Hypercoagulable States)
MLAB 1227: Coagulation Keri Brophy-Martinez Coagulation Disorders: Secondary Hemostasis Part Two.
THROMBOSIS Dr. Afsar Saeed Shaikh M.B.B.S, M.Phil. Assistant Professor of Chemical Pathology Pathology Department, KEMU, Lahore.
Disseminated Intravascular Coagulation. XIIa Coagulation cascade IIa Intrinsic system (surface contact ) XII XI XIa Tissue factor IX IXa VIIa VII VIIIVIIIa.
Thrombophilia National Haemophilia Director
Thrombophilia (Hypercoagulable States) Abdulkareem Almomen, MD Professor of Medicine & Hematology, King Saud University MED 341, Feb.2014.
Thrombophilia. Definition –Tendency to develop clots due to predisposing factors that may be genetically determined.
The Clotting Cascade and DIC Karim Rafaat, MD. Coagulation Coagulation is a host defense system that maintains the integrity of the high pressure closed.
Investigation of Haemostasis MS. c. program Lab-9.
Bleeding and Kristine Krafts, M.D. Thrombotic Disorders.
Hematology Blueprint PANCE Blueprint. Coagulation Disorders.
Protein C.  Protein C is a major physiological anticoagulant. anticoagulant  It is a vitamin K-dependent serine protease enzyme, that is activated by.
LABORATORY DIAGNOSIS OF PROTHROMBOTIC STATES. REGULATION OF COAGULATION Introduction Coagulation necessary for maintenance of vascular integrity Enough.
Deep vein thrombosis and pulmonary embolism.
Haemostasis. Indications for hemostasis test – Identify patients presenting with bleeding that have a correctable bleeding tendency – Identify patients.
Copyright © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 26 Disorders of Hemostasis.
1. Normal haemostasis Haemostasis is the process whereby haemorrhage following vascular injury is arrested. It depends on closely linked interaction.
Thrombosis and Haemostasis Café Cardiologique 29/10/2014.
Hemostasis Is a complex process which causes the bleeding process to stop. It refers to the process of keeping blood within a damaged blood vessel. Dependent.
Plasma and plasma components in the management of disseminated intravascular coagulation Marcel Levi* Academic Medical Center, University of Amsterdam,
Chapter 23. Bleeding disorders associated with coagulopathy
Bleeding Tendency Dr. Mervat Khorshied Ass. Prof. of Clinical and Chemical Pathology.
Obada Al-Eisa Saud Bashtawy Emad Mansour.  It is an acquired condition characterized by massive activation of the coagulation system.  It is always.
Venous Thromboembolism-1
Thrombosis.
CLS 223.
Hypercoagulable States
Constituents of the blood: Platelets and plasma
Thrombosis and embolism
Discounted Coagulation Profiles Clinical Laboratories.
and anti-thrombotic pharmocology Tom Williams
Bleeding and Thrombotic Disorders Kristine Krafts, M.D.
Drugs Affecting Blood.
Thrombophilia.
THROMBOSIS.
Hemostasis Hemostasis depends on the integrity of Blood vessels
Presentation transcript:

Tabuk University Faculty of Applied Medical Sciences Department Of Medical Lab. Technology 3 rd Year – Level 5 – AY

Thrombotic disorders 2 By/ Dr. Walid ZAMMITI; Phd M.Sc; MLT

Objectives Define terms used in thrombotic disorders. Identify the most common causes for thrombosis. Classify thrombosis into arterial and venous; and the differences between them. Classify thrombotic disorders into hereditary and acquired. Understand the mechanism of thrombosis in specific hereditary & acquired conditions. Learn the diagnostic tests used to identify genetic predisposition to thrombosis. 3

Disease processes Abnormal clotting 4 Abnormal bleeding Bleeding disorders : caused by Platelets, vascular, coagulation factors Thrombotic disorders

Thrombosis Thrombus: singular, Thrombi : Plural solid masses plugs Thrombi are solid masses or plugs formed in the circulation from blood constituents. ischaemia Platelets and fibrin form the basic structure. Their clinical significance results from ischaemia from local vascular obstruction or distant embolization. Thrombi are involved in the pathogenesis of myocardial infarction, cerebrovascular disease, peripheral arterial disease and deep vein occlusion. 5

6

Thrombosis may be arterial, causing ischemia, or venous leading to stasis. Thrombosis, both arterial and venous, is more common as age increases and is frequently associated with risk factors. thrombophilia The term thrombophilia is used to describe the inherited or acquired disorders of the haemostatic mechanism that predispose to thrombosis. 7

Arterial thrombosis Atherosclerosis تصلب الشرايين of the arterial wall, plaque rupture and endothelial injury expose blood to subendothelial collagen and tissue factor. This initiates the formation of a platelet plugs on which platelets adhere and aggregate. 8

Venous thrombosis three It is suggested that there are three components that are important in thrombus formation: 1. Slowing down of blood flow; 2.Hypercoagulability of the blood; and 3.Vessel wall damage. Increased systemic coagulability and stasis are most important, vessel wall damage being less important than in arterial thrombosis 9

Thrombotic disorders Hereditary Hereditary -Factor V Leiden gene mutation (activated protein C resistance) -Antithrombin deficiency -Protein C deficiency -Protein S deficiency -Prothrombin allele G20210A -Hyperhomocyst(e)inaemia -Defects of fibrinogen Acquired Acquired – Post surgery – Post delivery – Long distance travel – Immobilization – Malignancy – Inflammation – Blood disorders – Oestrogen therapy – The antiphospholipid syndrome – Factor IX concentrates 10

Activated Protein C (APC) Resistance (Factor V Leiden mutation) Genetic alterations of the factor V molecule at APC binding sites impair, or resist APC’s ability to degrade or inactivate factor Va. Site of mutation is replacement of arginine at position 506 with glutamine (Arg506Gln) in the factor V gene. venous It is the most common inherited cause of increased risk of venous thrombosis. It doesn’t increase risk of arterial thrombosis Diagnosed by PCR : Polymerase Chain Reaction. 11

Antithrombin Also known as Antithrombin III Antithrombin forms "complexes" with all the serine protease coagulation factors except factor VII, this "kills" the enzyme. 12 Prothrombin Thrombin ATIII inhibits thrombin to prevent thrombus formation Antithrombin III Fibrinogen Fibrin “Thrombus”

Antithrombin deficiency There are recurrent venous thromboses usually starting in early adult life. Arterial thrombi occur occasionally. 13

Protein C & S 14

15

Protein C and Protein C Deficiency Protein C is a vitamin K dependent glycoprotein produced in the liver In the activation of protein C, thrombin binds to thrombomodulin, a structural protein on the endothelial cell surface This complex then converts protein C to activated protein C (APC), which degrades factors Va and VIIIa, limiting thrombin production For protein C to bind, cleave and degrade factors Va and VIIIa, protein S must be available Protein C deficiency, whether inherited or acquired, may cause thrombosis when levels drop to 50% or below Protein C deficiency occurs with surgery, trauma, pregnancy, liver or renal failure or DIC. 16

Protein S, Protein S Deficiency cofactor Protein S is an essential cofactor in the protein C pathway Protein S exists in a free and bound state About 30% of unbound protein S, called free PS, is the functionally active form of protein S Inherited PS deficiency is an autosomal dominant disorder, causing thrombosis when levels drop to 50% or lower 17

Causes of Acquired Protein S Deficiency Decreased PS Functional activity may be due to : 1.vitamin K deficiency 2.liver disease 3.Due to increased PS consumption which occurs in acute thrombosis, DIC, MPD, sickle cell disease 18

Prothrombin gene mutation increased Prothrombin allele G20210A is a variant (prevalence 2- 3% in the population) that leads to increased plasma prothrombin levels and increases thrombotic risk by at least twofold. 19

Acquired risk factors of thrombosis 20

Post surgery: - Post surgery: elderly, obese & those with family history. Venous stasis and Immobilization : - Venous stasis and Immobilization : probably responsible for the high incidence of postoperative venous thrombosis. -Malignancy : -Malignancy : carcinoma of the ovary, brain and pancreas have a particularly increased risk of venous thrombosis but there is an increased risk with all cancers. -Inflammation : -Inflammation : down regulates anticoagulant pathways, particularly proteinC. Blood disorders : - Blood disorders :In polycythaemia vera and essential thrombocythaemia; there are Increased viscosity, thrombocytosis, altered platelet membrane receptors and responses. 21

Antiphospolipid syndrome Def: occurrence of thrombosis or miscarriage in association with antiphspholipid antibodies. * Antiphospholipid antibodies may be: Lupus anticoagulant (LA); causing prolonged APTT not corrected by mixing with normal plasma. Anticardiolipin antibodies (ACA). 22

Antiphospholipid Syndrome : Diagnosis Clinical association of (APA): -Arterial or venous thrombosis -Pregnancy loss -Thrombocytopenia -CNS stroke Laboratory Criteria -IgG or IgM anticardiolipin antibody-medium or high titer. -Detected in an ELISA assay 23

Oestrogen therapy Oestrogen therapy, particularly high-dose therapy, is associated with Increased plasma levels of factors II, VII, VIII, IX and X and, Depressed levels of antithrombin and tissue plasminogen activator in the vessel wall. 24

Investigation of thrombophilia Screening tests: Screening tests: -Blood count and erythrocyte sedimentation rate (ESR) -Blood film examination - Prothrombin time (PT) and APTT : (a shortened APPT is often seen in thrombotic states and may indicate the presence of activated clotting factors. A prolonged APTT test, not corrected by the addition of normal plasma, suggests a 'lupus anticoagulant‘ or an acquired inhibitor to a coagulation factor.) -Anticardiolipin and anti-β 2 -GPI antibodies - Thrombin time and reptilase time: (prolongation suggests an abnormal fibrinogen) 25

-Fibrinogen assay. - Activated protein C (APC) resistance test and DNA analysis for factor V Leiden. -Antithrombin-immunological and functional assays. - Protein C and protein S-immunological and functional assays. - Prothrombin gene analysis for the G20210A variant. - Plasma homocysteine estimation - Test for CD59 and CD55 expression (PNH) in red cells. (if paroxysmalnocturnal haemoglobinuria is suspected.) 26

Anticoagulant drugs Anticoagulant drugs are used widely in the treatment of venous thromboembolic disease. Their value in the treatment of arterial thrombosis is less well established. Heparin: laboratory controlled using APTT mainly. Oral anticoagulants : e.g : Warfarin, laboratory controlled using PT & INR (International Normalized Ratio). 27

THANK you 28